FZIOMED, INC.

Fziomed, Inc. is a global leader in surgical adhesion prevention, founded in 1996 and headquartered in San Luis Obispo, California. The company specializes in developing, manufacturing, and commercializing surgical biomaterials designed to prevent postsurgical adhesions—a common complication following surgical procedures. Fziomed's products utilize proprietary dual-polymer gel technology to create clear, absorbable formulations that provide temporary tissue separation during the healing process, significantly reducing adhesion formation. The company's flagship product, Oxiplex® gel, received FDA De Novo classification and marketing authorization in July 2025 for reducing postoperative leg pain and neurological symptoms in adult patients undergoing lumbar spine procedures. Fziomed's adhesion barrier products are marketed in over 70 countries and have been utilized in nearly 1 million procedures worldwide since 2002. The product portfolio addresses multiple surgical disciplines including spine surgery, tendon and peripheral nerve procedures, intrauterine surgery, and abdominal/pelvic procedures. With approximately 59 employees, Fziomed maintains full control over both manufacturing and commercialization of its innovative surgical solutions.